6533b86efe1ef96bd12cbc57

RESEARCH PRODUCT

G-CSF dosing schedule to prevent eribulin-induced neutropenia: Can modelling and simulation help?

Pierre FumoleauMaria Inês PereiraNicolas IsambertIsabelle DesmoulinsAntonin SchmittBruno Coudert

subject

OncologyCancer Researchmedicine.medical_specialtySchedulebusiness.industryNeutropeniamedicine.diseaseMetastatic breast cancerchemistry.chemical_compoundOncologychemistryInternal medicinemedicineMicrotubule InhibitorDosingIntensive care medicinebusinessEribulin

description

e20673 Background: Eribulin is a microtubule inhibitor indicated for the treatment of patients with metastatic breast cancer and should be administered on day 1 and 8 of each 21-day cycle. Neutrope...

https://doi.org/10.1200/jco.2015.33.15_suppl.e20673